BlackRock’s Augmedix, Inc. Common Stock AUGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-177,372
| Closed | -$417K | – | 5520 |
|
|
2024
Q3 | $417K | Buy |
177,372
+3,048
| +2% | +$6.15K | ﹤0.01% | 4372 |
|
|
2024
Q2 | $153K | Buy |
174,324
+20,803
| +14% | +$42.9K | ﹤0.01% | 4600 |
|
|
2024
Q1 | $628K | Sell |
153,521
-24,600
| -14% | -$110K | ﹤0.01% | 4317 |
|
|
2023
Q4 | $1.04M | Buy |
178,121
+59,639
| +50% | +$314K | ﹤0.01% | 4240 |
|
|
2023
Q3 | $610K | Buy |
118,482
+12,511
| +12% | +$58.7K | ﹤0.01% | 4369 |
|
|
2023
Q2 | $510K | Buy |
105,971
+68,814
| +185% | +$238K | ﹤0.01% | 4478 |
|
|
2023
Q1 | $64.7K | Buy |
37,157
+1,152
| +3% | +$1.88K | ﹤0.01% | 5065 |
|
|
2022
Q4 | $56.2K | Buy |
36,005
+768
| +2% | +$978 | ﹤0.01% | 5195 |
|
|
2022
Q3 | $51K | Sell |
35,237
-960
| -3% | -$1.65K | ﹤0.01% | 5345 |
|
|
2022
Q2 | $65K | Buy |
36,197
+35,103
| +3,209% | +$81.3K | ﹤0.01% | 5361 |
|
|
2022
Q1 | $3K | Hold |
1,094
| – | – | ﹤0.01% | 5726 |
|
|
2021
Q4 | $3K | Buy |
+1,094
| New | +$3.96K | ﹤0.01% | 5692 |
|
BlackRock's AUGX Position: Q4 2024 in Review
BlackRock sold out of Augmedix, Inc. Common Stock (AUGX) in Q4 2024, closing a stake of 177,372 shares — an estimated $417K sold.
BlackRock first reported a position in AUGX in Q4 2021 and held it in 12 quarters. The position peaked at $1.04M in Q4 2023. 0 funds tracked by Wall St. Rank hold AUGX as of Q4 2024.
- BlackRock reported no remaining Augmedix, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 177,372 Augmedix, Inc. Common Stock shares in Q4 2024, an estimated $417K.
- BlackRock first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 12 quarters.
- BlackRock's Augmedix, Inc. Common Stock position peaked at $1.04M in Q4 2023.
- 0 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.